{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:17:39Z","timestamp":1792581459851,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["K\/ZDS\/006166 and N41\/DBS\/000506"],"award-info":[{"award-number":["K\/ZDS\/006166 and N41\/DBS\/000506"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Central retinal artery occlusion (CRAO) is a common cause of blindness and visual morbidity. In the majority of cases, it is related to thrombotic embolism. Nevertheless, the role of inherited or acquired thrombophilic risk factors in CRAO pathogenesis has not been comprehensively studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In 126 CRAO patients (66 [52.4%] men, median age 55 [range: 18\u201380] years) and 107 matched controls (56 [52.3%] men, median age 53 [range: 34\u201378] years) we evaluated classical atherosclerotic risk factors, including serum lipid profile and glucose level, analyzed intima-media complex thickness (IMT) of external carotid arteries, and performed transthoracic echocardiography. Furthermore, we established the prevalence of inherited and acquired thrombophilic risk factors, such as factor V Leiden (FVL) and prothrombin 20210 G\/A genetic variants, plasma activity of factor (F) VIII, protein C and antithrombin activity, and free protein S levels. We also assessed the presence of antiphospholipid antibodies (APLA) and evaluated blood homocysteine in all enrolled subjects. Additionally, we estimated the occurrence of Val34Leu polymorphism of the A subunit of coagulation factor XIII (FXIII-A) in both groups as a potential thrombosis-protecting factor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among traditional atherosclerotic risk components, obesity\/overweight and hypercholesterolemia were the most common in the CRAO group and occurred in 103 (81.7%) and 85 (67.5%) patients, respectively. CRAO patients also had elevated IMT and altered echocardiographic parameters, indicating diastolic cardiac dysfunction. In thrombophilia investigations, at least one laboratory risk factor occurred in 72.2% (n\u2009=\u200991) of CRAO patients, with APLA as the most frequent, detected in 38.1% (n\u2009=\u200948) of them (almost seven times more frequent than in controls, p\u2009&lt;\u20090.001). Deficiencies in protein C activity and free protein S levels were also common in the CRAO group, reported in 17.5% (n\u2009=\u200922) and 19.8% (n\u2009=\u200925) of patients, respectively. Interestingly, among two analyzed prothrombotic genetic variants, only the FVL was related to CRAO, with the allelic frequency 2.4 times more prevalent than in controls (p\u2009=\u20090.044). Finally, the CRAO group was characterized by hyperhomocysteinemia, almost twice as common as in controls (p\u2009=\u20090.026). Antithrombin deficiency, elevated FVIII, and FXIII-A Val34Leu polymorphism were not associated with CRAO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that thrombophilia plays a vital role in the pathogenesis of CRAO. Thus, proper laboratory screening should be considered in the primary and secondary prevention of those episodes, with implementing appropriate therapy as needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12959-023-00525-z","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T18:02:59Z","timestamp":1690567379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["High prevalence of thrombophilic risk factors in patients with central retinal artery occlusion"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0321-3557","authenticated-orcid":false,"given":"Rados\u0142aw","family":"Dziedzic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2221-614X","authenticated-orcid":false,"given":"Lech","family":"Zar\u0119ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-9242","authenticated-orcid":false,"given":"Teresa","family":"Iwaniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2859-4149","authenticated-orcid":false,"given":"Agnieszka","family":"Kubicka-Trz\u0105ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6940-5485","authenticated-orcid":false,"given":"Bo\u017cena","family":"Romanowska-Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-0963","authenticated-orcid":false,"given":"Stanis\u0142awa","family":"Bazan-Socha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0768-5597","authenticated-orcid":false,"given":"Jerzy","family":"Dropi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"525_CR1","doi-asserted-by":"publisher","unstructured":"Mac Grory B, et al. Management of Central Retinal artery occlusion: a Scientific Statement from the American Heart Association. Stroke. Jun. 2021;52(6). https:\/\/doi.org\/10.1161\/STR.0000000000000366.","DOI":"10.1161\/STR.0000000000000366"},{"key":"525_CR2","doi-asserted-by":"publisher","unstructured":"Biousse V, Nahab F, Newman NJ. Management of Acute Retinal Ischemia. Ophthalmology. Oct. 2018;125(10):1597\u2013607. https:\/\/doi.org\/10.1016\/j.ophtha.2018.03.054.","DOI":"10.1016\/j.ophtha.2018.03.054"},{"key":"525_CR3","doi-asserted-by":"publisher","unstructured":"Marcucci R et al. \u201cCardiovascular and thrombophilic risk factors in patients with retinal artery occlusion,\u201d Blood Coagul. Fibrinolysis, vol.\u00a018, no. 4, pp.\u00a0321\u2013326, Jun. 2007, doi: https:\/\/doi.org\/10.1097\/MBC.0b013e32809cc922.","DOI":"10.1097\/MBC.0b013e32809cc922"},{"key":"525_CR4","doi-asserted-by":"publisher","unstructured":"Roskal-Wa\u0142ek J, et al. Retinal artery occlusion and its impact on the incidence of stroke, myocardial infarction, and all-cause mortality during 12-Year Follow-Up. J Clin Med. Jul. 2022;11(14):4076. https:\/\/doi.org\/10.3390\/jcm11144076.","DOI":"10.3390\/jcm11144076"},{"key":"525_CR5","doi-asserted-by":"publisher","unstructured":"Terao R, Fujino R, Ahmed T. \u201cRisk Factors and Treatment Strategy for Retinal Vascular Occlusive Diseases,\u201d J. Clin. Med, vol.\u00a011, no. 21, p.\u00a06340, Oct. 2022, doi: https:\/\/doi.org\/10.3390\/jcm11216340.","DOI":"10.3390\/jcm11216340"},{"key":"525_CR6","doi-asserted-by":"publisher","unstructured":"Huang L, Wang Y, Zhang R. Intravenous thrombolysis in patients with central retinal artery occlusion: a systematic review and meta-analysis. J Neurol. Apr. 2022;269(4):1825\u201333. https:\/\/doi.org\/10.1007\/s00415-021-10838-6.","DOI":"10.1007\/s00415-021-10838-6"},{"key":"525_CR7","doi-asserted-by":"publisher","unstructured":"Campello E, Spiezia L, Adamo A, Simioni P. \u201cThrombophilia, risk factors and prevention,\u201d Expert Rev. Hematol, vol.\u00a012, no. 3, pp.\u00a0147\u2013158, Mar. 2019, doi: https:\/\/doi.org\/10.1080\/17474086.2019.1583555.","DOI":"10.1080\/17474086.2019.1583555"},{"key":"525_CR8","doi-asserted-by":"publisher","unstructured":"W\u00f3jcik K, et al. Decreased protein C activity, lower ADAMTS13 antigen and free protein S levels accompanied by unchanged thrombin generation potential in hospitalized COVID-19 patients. Thromb Res. Mar. 2023;223:80\u20136. https:\/\/doi.org\/10.1016\/j.thromres.2023.01.016.","DOI":"10.1016\/j.thromres.2023.01.016"},{"key":"525_CR9","doi-asserted-by":"publisher","unstructured":"Kujovich JL. Factor V Leiden thrombophilia. Genet Med. Jan. 2011;13(1):1\u201316. https:\/\/doi.org\/10.1097\/GIM.0b013e3181faa0f2.","DOI":"10.1097\/GIM.0b013e3181faa0f2"},{"key":"525_CR10","doi-asserted-by":"publisher","unstructured":"Nguyen A. \u201cProthrombin G20210A Polymorphism and Thrombophilia,\u201d Mayo Clin. Proc, vol.\u00a075, no. 6, pp.\u00a0595\u2013604, Jun. 2000, doi: https:\/\/doi.org\/10.4065\/75.6.595.","DOI":"10.4065\/75.6.595"},{"key":"525_CR11","doi-asserted-by":"publisher","unstructured":"Rosenberg RD, Bauer KA. \u201cThrombosis in inherited deficiencies of antithrombin, protein C, and protein S,\u201d Hum. Pathol, vol.\u00a018, no. 3, pp.\u00a0253\u2013262, Mar. 1987, doi: https:\/\/doi.org\/10.1016\/S0046-8177(87)80008-4.","DOI":"10.1016\/S0046-8177(87)80008-4"},{"key":"525_CR12","doi-asserted-by":"publisher","unstructured":"Bravo-P\u00e9rez C, Vicente V, Corral J. \u201cManagement of antithrombin deficiency: an update for clinicians,\u201d Expert Rev. Hematol, vol.\u00a012, no. 6, pp.\u00a0397\u2013405, Jun. 2019, doi: https:\/\/doi.org\/10.1080\/17474086.2019.1611424.","DOI":"10.1080\/17474086.2019.1611424"},{"key":"525_CR13","doi-asserted-by":"publisher","unstructured":"Gatt A, Makris M. \u201cHyperhomocysteinemia and Venous Thrombosis,\u201d Semin. Hematol, vol.\u00a044, no. 2, pp.\u00a070\u201376, Apr. 2007, doi: https:\/\/doi.org\/10.1053\/j.seminhematol.2007.01.002.","DOI":"10.1053\/j.seminhematol.2007.01.002"},{"key":"525_CR14","doi-asserted-by":"publisher","unstructured":"Wong R, Favaloro E. \u201cClinical Features, Diagnosis, and Management of the Antiphospholipid Syndrome,\u201d Semin. Thromb. Hemost, vol.\u00a034, no. 03, pp.\u00a0295\u2013304, Apr. 2008, doi: https:\/\/doi.org\/10.1055\/s-0028-1082275.","DOI":"10.1055\/s-0028-1082275"},{"key":"525_CR15","doi-asserted-by":"publisher","unstructured":"Ghembaza A, Saadoun D. Management of Antiphospholipid Syndrome. Biomedicines. Nov. 2020;8(11):508. https:\/\/doi.org\/10.3390\/biomedicines8110508.","DOI":"10.3390\/biomedicines8110508"},{"key":"525_CR16","doi-asserted-by":"publisher","unstructured":"Tektonidou MG. Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis. J Autoimmun. Apr. 2022;128:102813. https:\/\/doi.org\/10.1016\/j.jaut.2022.102813.","DOI":"10.1016\/j.jaut.2022.102813"},{"key":"525_CR17","doi-asserted-by":"publisher","unstructured":"Marcinkowska A, Cisiecki S, Rozalski M. \u201cPlatelet and Thrombophilia-Related Risk Factors of Retinal Vein Occlusion,\u201d J. Clin. Med, vol.\u00a010, no. 14, p.\u00a03080, Jul. 2021, doi: https:\/\/doi.org\/10.3390\/jcm10143080.","DOI":"10.3390\/jcm10143080"},{"key":"525_CR18","doi-asserted-by":"publisher","unstructured":"Nagy V. Thrombophilic screening in retinal artery occlusion patients. Clin Ophthalmol. p. Oct. 2008;557. https:\/\/doi.org\/10.2147\/OPTH.S1512.","DOI":"10.2147\/OPTH.S1512"},{"key":"525_CR19","doi-asserted-by":"publisher","unstructured":"Glueck C, Hutchins RK, Jurante J, Khan Z, Wang P. Thrombophilia and retinal vascular occlusion. Clin Ophthalmol. p. Aug. 2012;1377. https:\/\/doi.org\/10.2147\/OPTH.S34627.","DOI":"10.2147\/OPTH.S34627"},{"issue":"3","key":"525_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/a:1010639332737","volume":"23","author":"K Greiner","year":"1999","unstructured":"Greiner K, Peetz D, Winkgen A, Prellwitz W, Pfeiffer N, Hafner G. Genetic thrombophilia in patients with retinal vascular occlusion. \u201d Int Ophthalmol. 1999;23(3):155\u201360. https:\/\/doi.org\/10.1023\/a:1010639332737.","journal-title":"\u201d Int Ophthalmol"},{"issue":"1","key":"525_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000096521","volume":"221","author":"AM Palmowski-Wolfe","year":"2007","unstructured":"Palmowski-Wolfe AM, Denninger E, Geisel J, Pindur G, Ruprecht KW. Antiphospholipid antibodies in ocular arterial and venous occlusive disease. Ophthalmologica. 2007;221(1):41\u20136. https:\/\/doi.org\/10.1159\/000096521.","journal-title":"Ophthalmologica"},{"key":"525_CR22","doi-asserted-by":"publisher","unstructured":"Huang X, Yang Y, Duan Y, Kuang Y-Q, Lin D. Homocysteine in retinal artery occlusive disease: a meta-analysis of cohort studies. Sci Rep. Dec. 2017;7(1):15708. https:\/\/doi.org\/10.1038\/s41598-017-16065-2.","DOI":"10.1038\/s41598-017-16065-2"},{"key":"525_CR23","doi-asserted-by":"publisher","unstructured":"Cahill MT, Stinnett SS, Fekrat S. \u201cMeta-analysis of plasma homocysteine, serum folate, serum vitamin B12, and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease,\u201d Am. J. Ophthalmol, vol.\u00a0136, no. 6, pp.\u00a01136\u20131150, Dec. 2003, doi: https:\/\/doi.org\/10.1016\/S0002-9394(03)00571-3.","DOI":"10.1016\/S0002-9394(03)00571-3"},{"key":"525_CR24","doi-asserted-by":"publisher","unstructured":"Chua B, Kifley A, Wong TY, Mitchell P. \u201cHomocysteine and Retinal Emboli: The Blue Mountains Eye Study,\u201d Am. J. Ophthalmol, vol.\u00a0142, no. 2, pp.\u00a0322\u2013324, Aug. 2006, doi: https:\/\/doi.org\/10.1016\/j.ajo.2006.03.039.","DOI":"10.1016\/j.ajo.2006.03.039"},{"issue":"4","key":"525_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000446028","volume":"235","author":"C Kuhli-Hattenbach","year":"2016","unstructured":"Kuhli-Hattenbach C, Hellstern P, Miesbach W, Kohnen T, Hattenbach L-O. Selective Thrombophilia Screening in Young patients with retinal artery occlusion. Ophthalmologica. 2016;235(4):189\u201394. https:\/\/doi.org\/10.1159\/000446028.","journal-title":"Ophthalmologica"},{"key":"525_CR26","doi-asserted-by":"publisher","unstructured":"Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with Common Thrombophilia. Arch Intern Med. Apr. 2006;166(7):729. https:\/\/doi.org\/10.1001\/archinte.166.7.729.","DOI":"10.1001\/archinte.166.7.729"},{"key":"525_CR27","doi-asserted-by":"publisher","unstructured":"Stein JH et al. \u201cUse of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular,\u201d J. Am. Soc. Echocardiogr, vol.\u00a021, no. 2, pp.\u00a093\u2013111, Feb. 2008, doi: https:\/\/doi.org\/10.1016\/j.echo.2007.11.011.","DOI":"10.1016\/j.echo.2007.11.011"},{"key":"525_CR28","doi-asserted-by":"publisher","unstructured":"Hillis GS, Bloomfield P. \u201cBasic transthoracic echocardiography,\u201d BMJ, vol.\u00a0330, no. 7505, pp.\u00a01432\u20131436, Jun. 2005, doi: https:\/\/doi.org\/10.1136\/bmj.330.7505.1432.","DOI":"10.1136\/bmj.330.7505.1432"},{"issue":"12","key":"525_CR29","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.4103\/ijo.IJO_1446_18","volume":"66","author":"S Hayreh","year":"2018","unstructured":"Hayreh S. Central retinal artery occlusion. Indian J Ophthalmol. 2018;66(12):1684. https:\/\/doi.org\/10.4103\/ijo.IJO_1446_18.","journal-title":"Indian J Ophthalmol"},{"key":"525_CR30","doi-asserted-by":"publisher","unstructured":"Dropi\u0144ski J et al. \u201cCentral Retinal Artery Occlusion Is Related to Vascular Endothelial Injury and Left Ventricular Diastolic Dysfunction,\u201d J. Clin. Med, vol.\u00a011, no. 8, p.\u00a02263, Apr. 2022, doi: https:\/\/doi.org\/10.3390\/jcm11082263.","DOI":"10.3390\/jcm11082263"},{"key":"525_CR31","doi-asserted-by":"publisher","unstructured":"Devreese KMJ et al. \u201cGuidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis,\u201d J. Thromb. Haemost, vol.\u00a018, no. 11, pp.\u00a02828\u20132839, Nov. 2020, doi: https:\/\/doi.org\/10.1111\/jth.15047.","DOI":"10.1111\/jth.15047"},{"key":"525_CR32","doi-asserted-by":"publisher","unstructured":"Juul K, Tybj\u00e6rg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult danish Population. Ann Intern Med. Mar. 2004;140(5):330. https:\/\/doi.org\/10.7326\/0003-4819-140-5-200403020-00008.","DOI":"10.7326\/0003-4819-140-5-200403020-00008"},{"key":"525_CR33","doi-asserted-by":"publisher","unstructured":"Weischer M, et al. Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population. Atherosclerosis. Feb. 2010;208(2):480\u20133. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.05.006.","DOI":"10.1016\/j.atherosclerosis.2009.05.006"},{"key":"525_CR34","doi-asserted-by":"publisher","unstructured":"Shemirani AH, Muszbek L. Rapid detection of the factor XIII Val34Leu (163 G\u2192T) polymorphism by real-time PCR using fluorescence resonance energy transfer detection and melting curve analysis. Clin Chem Lab Med. Jan. 2004;42(8). https:\/\/doi.org\/10.1515\/CCLM.2004.142.","DOI":"10.1515\/CCLM.2004.142"},{"key":"525_CR35","doi-asserted-by":"publisher","unstructured":"Romiti GF et al. \u201cInherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta-analysis,\u201d J. Thromb. Haemost, vol.\u00a018, no. 12, pp.\u00a03249\u20133266, Dec. 2020, doi: https:\/\/doi.org\/10.1111\/jth.15068.","DOI":"10.1111\/jth.15068"},{"key":"525_CR36","doi-asserted-by":"publisher","unstructured":"Chaturvedi S, McCrae KR. \u201cThe antiphospholipid syndrome: still an enigma.,\u201d Hematol. Am. Soc. Hematol. Educ. Progr, vol. 2015, pp.\u00a053\u201360, 2015, doi: https:\/\/doi.org\/10.1182\/asheducation-2015.1.53.","DOI":"10.1182\/asheducation-2015.1.53"},{"key":"525_CR37","doi-asserted-by":"publisher","unstructured":"Rand JH. \u201cDetection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome,\u201d Blood, vol.\u00a0104, no. 9, pp.\u00a02783\u20132790, Nov. 2004, doi: https:\/\/doi.org\/10.1182\/blood-2004-01-0203.","DOI":"10.1182\/blood-2004-01-0203"},{"key":"525_CR38","doi-asserted-by":"publisher","unstructured":"Hulstein JJJ, Lenting PJ, de Laat B, Derksen RHWM, Fijnheer R, de Groot PG. \u201c\u03b22-Glycoprotein I inhibits von Willebrand factor\u2013dependent platelet adhesion and aggregation,\u201d Blood, vol.\u00a0110, no. 5, pp.\u00a01483\u20131491, Sep. 2007, doi: https:\/\/doi.org\/10.1182\/blood-2006-10-053199.","DOI":"10.1182\/blood-2006-10-053199"},{"key":"525_CR39","doi-asserted-by":"publisher","unstructured":"Giannakopoulos B, Krilis SA. \u201cThe Pathogenesis of the Antiphospholipid Syndrome,\u201d N. Engl. J. Med, vol.\u00a0368, no. 11, pp.\u00a01033\u20131044, Mar. 2013, doi: https:\/\/doi.org\/10.1056\/NEJMra1112830.","DOI":"10.1056\/NEJMra1112830"},{"key":"525_CR40","doi-asserted-by":"publisher","unstructured":"Bank I, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. Jan. 2005;3(1):79\u201384. https:\/\/doi.org\/10.1111\/j.1538-7836.2004.01033.x.","DOI":"10.1111\/j.1538-7836.2004.01033.x"},{"key":"525_CR41","doi-asserted-by":"publisher","unstructured":"Andreotti F, Burzotta F, Manzoli A, Robinson K. \u201cHomocysteine and risk of cardiovascular disease.,\u201d J. Thromb. Thrombolysis, vol.\u00a09, no. 1, pp.\u00a013\u201321, Jan. 2000, doi: https:\/\/doi.org\/10.1023\/a:1018675624181.","DOI":"10.1023\/a:1018675624181"},{"key":"525_CR42","doi-asserted-by":"publisher","unstructured":"Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med. Feb. 2009;60(1):39\u201354. https:\/\/doi.org\/10.1146\/annurev.med.60.041807.123308.","DOI":"10.1146\/annurev.med.60.041807.123308"},{"key":"525_CR43","doi-asserted-by":"publisher","unstructured":"Mart\u00ed-Carvajal AJ, Sol\u00e0 I, Lathyris D, Dayer M. \u201cHomocysteine-lowering interventions for preventing cardiovascular events,\u201d Cochrane Database Syst. Rev, vol. 2021, no. 9, Aug. 2017, doi: https:\/\/doi.org\/10.1002\/14651858.CD006612.pub5.","DOI":"10.1002\/14651858.CD006612.pub5"},{"key":"525_CR44","doi-asserted-by":"publisher","unstructured":"Weger M, et al. Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion. Eye. Aug. 2003;17(6):731\u20134. https:\/\/doi.org\/10.1038\/sj.eye.6700495.","DOI":"10.1038\/sj.eye.6700495"},{"key":"525_CR45","doi-asserted-by":"publisher","unstructured":"Bagoly Z, Koncz Z, H\u00e1rsfalvi J, Muszbek L. Factor XIII, clot structure, thrombosis. Thromb Res. Mar. 2012;129(3):382\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2011.11.040.","DOI":"10.1016\/j.thromres.2011.11.040"},{"key":"525_CR46","doi-asserted-by":"publisher","unstructured":"Weger M et al. \u201cRole of Factor XIII Val34Leu Polymorphism in Retinal Artery Occlusion,\u201d Stroke, vol.\u00a032, no. 12, pp.\u00a02759\u20132761, Dec. 2001, doi: https:\/\/doi.org\/10.1161\/hs1201.99889.","DOI":"10.1161\/hs1201.99889"},{"key":"525_CR47","doi-asserted-by":"publisher","unstructured":"Stevens SM, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. Jan. 2016;41(1):154\u201364. https:\/\/doi.org\/10.1007\/s11239-015-1316-1.","DOI":"10.1007\/s11239-015-1316-1"},{"key":"525_CR48","doi-asserted-by":"publisher","unstructured":"Capecchi M, Abbattista M, Ciavarella A, Uhr M, Novembrino C, Martinelli I. Anticoagulant therapy in patients with antiphospholipid syndrome. J Clin Med. Nov. 2022;11(23):6984. https:\/\/doi.org\/10.3390\/jcm11236984.","DOI":"10.3390\/jcm11236984"},{"key":"525_CR49","doi-asserted-by":"publisher","unstructured":"Dufrost V, Wahl D, Zuily S. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials. Autoimmun Rev. Jan. 2021;20(1):102711. https:\/\/doi.org\/10.1016\/j.autrev.2020.102711.","DOI":"10.1016\/j.autrev.2020.102711"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-023-00525-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-023-00525-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-023-00525-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T18:03:40Z","timestamp":1690567420000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-023-00525-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1186\/s12959-023-00525-z","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"8 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The following research provides single-center data and has a case-control type, and was approved by the Bioethics Committee of the Jagiellonian University Medical College (permit No: KBET\/79\/B\/2013). The study procedures were carried out under the ethical guidelines of the Declaration of Helsinki. All participants gave informed consent in writing to participate in the study. Therefore, the study could be further published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"81"}}